Gemini Therapeutics

51 articles about Gemini Therapeutics

• Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration

  10/15/2020

  Leading institutional investors commit $95 million through a common stock private investment in public equity (“PIPE”) led by Foresite Capital, as well as Fidelity Management & Research Company LLC, Wellington Management, Boxer Capital of Tavistock Group, Alyeska Investment Group, L.P., Suvretta Capital Management, CVF, DAFNA Capital, and Acorn Bioventures – - Total proceeds from this transaction are expected to be approximately $216 million, com

• Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration

  9/10/2020

  -  Enrollment initiated in Phase 1 MAD study in patients with high-risk genetic variants for dry AMD –    -  Phase 1 topline results demonstrate promising safety profile, with no treatment-related adverse events as well as PK and biomarker changes in genetically defined dry AMD -   CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-

• Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent Director

  8/27/2020

  Ophthalmology innovator brings more than 20 years of clinical and drug development experience to the Board of Directors

• Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer

  5/7/2020

  Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Marc E. Uknis MD, FACS has been appointed to serve as Chief Medical Officer, effective today. Dr. Uknis brings more than 35 years of experience in industry and academia in research programs across various areas including surgery,

• Gemini Therapeutics Appoints David Lubner as Independent Director

  4/28/2020

  Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration and linked ocular disorders, announced that David Lubner has been appointed to serve as an independent member of its Board of Directors.

• Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular Degeneration

  2/26/2020

  Feb. 26, 2020 12:00 UTC CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore the link between genetic and poten

• Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration

  1/9/2020

  Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry age-related macular degeneration (AMD) and linked ocular disorders, today announced it has initiated enrollment in its Phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration

• Gemini Therapeutics Announces Leadership Appointment

  9/13/2019

  Gemini Therapeutics, a precision medicine company developing innovative treatments for age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Jason Meyenburg, MBA, as Chief Executive Officer (CEO).

• Gemini Therapeutics Announces the Initiation of CLARITY, a Disease Registry and Natural History Study of Subjects with Dry AMD and High-Risk Genotypes

  1/7/2019

  Gemini initiates the largest and most complete longitudinal prospective clinical study to date of subjects with dry Age-Related Macular Degeneration (AMD) who are carriers of high-risk genotypes

• Gemini Therapeutics Strengthens Senior Leadership Team with Key Appointments and Promotion

  5/30/2018

  Precision medicine company names Chief Medical Officer, Chief Business Officer and Chief Technology Officer.

• 

  Gemini Therapeutics Banks $42.5M to Bring Precision Med to AMD

  10/17/2017

  Backed by Atlas Venture, Lightstone Ventures and OrbiMed, Gemini has emerged with $42.5M in Series A funding and a focus on rare genetic diseases.